Fig. 6

PEG10 overexpression is associated with disease recurrence and CDK4/6 inhibitor resistance in breast cancer patients. A Kaplan–Meier survival curves of RFS in HR+ breast cancer according to relative PEG10 mRNA expression from public mRNA microarray data set of GSE 6532. GSE 6532 analysis was performed using self-downloaded processed data. B-D Kaplan–Meier survival curves of RFS in HR+ breast cancer according to relative PEG10 mRNA expression from public mRNA microarray data sets of B GSE 2034, C E-MTAB-365, and D GSE 3494. Analyses of these data sets were performed using online platform Kaplan–Meier plotter (https://kmplot.com/analysis/). E Univariate and multivariate analysis of prognosticators for RFS in GSE 6532. F IHC staining of PEG10 in patients’ tumor specimens. Negative control (placental tissue, without primary antibody) and positive control (placental tissue, with primary antibody) are shown in the left panel. Representative images of negative and positive PEG10 IHC in pre-CDK4/6 inhibitor treatment tissue are shown in the right panel. G Kaplan–Meier survival curves of PFS according to PEG10 expression by IHC in pre-CDK4/6 inhibitor treatment tissue. H Schematic diagram showing the proposed mechanism that explains how PEG10 is associated with CDK4/6 inhibitors resistance. Abbreviations: RFS, recurrence-free survival; HR (in table of figure), hazard ratio; PFS, progression-free survival; Cut-off for PEG10-High versus PEG10-Low is the upper quartile